|
3.1 Prévention - Tabac
|
|
|
|
4.12 Biopsies liquides
|
|
|
|
5.10 Traitements - Essais
|
|
|
|
5.12 Immunothérapies
|
|
|
|
5.12.1 Immunothérapies - partenariats
|
|
|
|
5.12.2 Immunothérapies - CAR-T
|
|
|
|
5.2 Pharma
|
|
|
Novartis loses top oncology executive Strigini to retirement [FiercePharma]
|
|
|
|
|
|
Just
before Strigini joined Novartis, the company agreed to its massive
asset swap with GSK, offloading its vaccine programs—besides flu—in
exchange for Glaxo's cancer offerings. Outgoing Novartis CEO Joe Jimenez
called the deal "transformational" when it was announced as it would
ultimately propel the drugmaker to a leadership position in oncology.
|
|
|
|
|
|
|
5.2.1 Pharma - Partenariats
|
|
|
|
5.3 Traitements - FDA, EMA, NICE...
|
|
|
EU drugs agency says move to new HQ may take longer [Reuters]
|
|
|
|
|
|
A
spokeswoman for the city of Amsterdam on Friday said there had been no
change in its plans for EMA. She said, the building will be completed in
two stages and should be ready to accommodate all employees at the
beginning of 2020 as promised.
|
|
|
|
|
|
|
|
5.3.4 Traitements - AMM (FDA, EMA)
|
|
|
|
5.4 Traitements - Economie
|
|
|
|
|
6. Lutte contre les cancers
|
|
|
NCI: Taking Risks to Advance Science [NCI]
|
|
|
|
|
|
Currently,
we are very good at describing the stage, pathology, and specific
molecular features of a cancer. Yet, we still aren’t sufficiently adept
at telling patients what they really want to know: what treatment will
work given the underlying biology of their tumor. And that is very
frustrating to both patients and clinicians.
|
|
|
|
|
|
|
|
6.1 Observation
|
|
|
|
6.10.1 Politiques (USA)
|
|
|
|
|
6.11 Patients
|
|
|